|
Poland Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Poland Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Poland.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Polish pharmaceutical and healthcare industry.
Competitive intelligence, Polish pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Polish market.
The Poland Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Poland Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Polish pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Poland to test other views – a key input for successful budgeting and strategic business planning in the Polish pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Polish Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Poland.
- Exploit The Latest Competitive Polish Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Poland.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Poland Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Poland Pharmaceuticals Industry SWOT |
| Poland Political SWOT |
| Poland Economic SWOT |
| Poland Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Central And Eastern Europe Business Environment Ratings For Q209 |
| Limits Of Potential Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Intellectual Property Developments |
| Pricing And Reimbursement Issues |
| Marketing |
Chapter - Industry Developments |
| Healthcare Overview |
| Healthcare Reforms |
| Health Insurance |
| Epidemiology |
| Table: Disease Burden In CEE |
| Research And Development |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Poland's Drug Market Indicators |
| Key Growth Factors – Industry |
| Table: Poland's Health Expenditure Indicators |
| Key Growth Factors – Macroeconomic |
| Table: Poland – Economic Activity |
| Prescription Market Forecast |
| Table: Poland – Prescription Market Indicators, 2004-2013 (US$mn unless otherwise stated) |
| OTC Market Forecast |
| Table: OTC Market Indicators (US$mn unless otherwise stated) |
| Patented Market Forecast |
| Table: Poland's Patented Market Forecast, 2004-2013 |
| Generics Market Forecast |
| Table: Poland's Generics Market Indicators, 2004-2013 |
| Medical Device Market Forecast |
| Table: Poland's Medical Device Market Indicators, 2004-201 (US$mn unless otherwise stated) |
| Trade Figures |
| Table: Poland's Pharmaceutical Trade Indicators, 2004-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Socio-Demographic Indicators, 2004-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Domestic Industry |
| Domestic Company Developments |
| Foreign Industry |
| Foreign Company Developments |
| Biotechnology Sector |
| Wholesale Sector |
| Retail Sector |
| Table: Poland's Pharmacies And Pharmacy Market Ratios, 2004-2009 |
Chapter - Company Monitor |
| GlaxoSmithKline |
| Eli Lilly |
| Gedeon Richter |
| Krka |
| Lek (Novartis/Sandoz) |
| Polpharma |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Poland Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Top line data for pharmaceutical sales in Poland suggest that the market holds significant potential for drugmakers. Healthy levels of growth, coupled with an already substantial market size, saw per capita spending rise to US$215 in 2008. Through to 2013, sales of pharmaceuticals, which include prescription drugs and over-the-counter medicines, will increase from US$8.2bn, to US$10.9bn, representing a compound annual growth rate (CAGR) of 5.9%. This rate remains higher than the majority of Western European countries.
Despite market expansion, negative market risks are a major drawback for innovative firms and a key reason for the country’s fourth place in the rankings among the 20 countries in BMI’s Pharmaceutical Business Environment Rankings for Central and Eastern Europe (CEE) in Q209. The regulatory environment is characterised by long delays for reimbursement approval and a heavily pro-generic and pro-domestic regime. In addition, high levels of patient co-payments mean that more expensive products are out of many patients’ reach.
Recent developments have provided for some positive progress, however. In late 2008, the Ministry of Health took an encouraging step towards improving access to patented treatments, with the release of a new reimbursement list. While the list consisted mainly of generic drugs, a number of new molecules and orphan products were also included. Changes to the list are estimated to add around EUR200mn a year to government pharmaceutical expenditure. Meanwhile, in early 2009, the drawn-out process of updating regulations took a step forward. By harmonising drug documentation, the Ministry of Health reduced the number of authorised drugs on the market by over 2,500.
While there has been some improvements in patient access to modern and effective treatments, pharmaceutical marketing has become significantly more restricted in 2009. Under new regulations, doctors may only meet representatives at specified times outside working hours. In addition, doctors must seek approval from the head of the clinic or hospital where they work. In addition negotiations between company representatives and government officials must also now be recorded, as the state seeks to increase transparency.
The operating environment is likely to remain challenging for pharmaceutical companies over the medium-term, however upsides exist for foreign drugmakers. Generics companies will see significant benefit from market growth and state policies. In recognition of this, US-based Mylan has announced it will add another 30 products to its portfolio in 2009. Meanwhile, in an effort to maximise returns, as many as seven pharmaceutical companies are following AstraZeneca’s lead in considering direct-to-pharmacy (DTP) distribution in Poland.
|
Poland Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |